Latest Insider Transactions at Mi Nk Therapeutics, Inc. (INKT)
This section provides a real-time view of insider transactions for Mi Nk Therapeutics, Inc. (INKT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MiNK Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MiNK Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2023
|
Agenus Inc |
SELL
Other acquisition or disposition
|
Direct |
4,988,273
-18.94%
|
-
|
|
Mar 01
2023
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
6,699
+13.55%
|
$13,398
$2.09 P/Share
|
|
Mar 01
2023
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
8,553
+2.71%
|
$17,106
$2.09 P/Share
|
|
Mar 01
2023
|
John Baldoni |
BUY
Grant, award, or other acquisition
|
Direct |
6,878
+22.75%
|
$13,756
$2.09 P/Share
|
|
Mar 01
2023
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
7,357
+22.75%
|
$14,714
$2.09 P/Share
|
|
Mar 01
2023
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
8,493
+22.75%
|
$16,986
$2.09 P/Share
|
|
Jan 09
2023
|
Marcus Antonius Van Dijk Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,265
-47.0%
|
$48,530
$2.32 P/Share
|
|
Jan 09
2023
|
Marcus Antonius Van Dijk Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,628
+50.0%
|
$103,256
$2.32 P/Share
|
|
Jan 09
2023
|
Jennifer Buell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
171,990
+31.12%
|
$343,980
$2.32 P/Share
|
|
Dec 01
2022
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,364
+12.95%
|
$10,728
$2.61 P/Share
|
|
Dec 01
2022
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
5,891
+25.05%
|
$11,782
$2.61 P/Share
|
|
Dec 01
2022
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
6,801
+25.05%
|
$13,602
$2.61 P/Share
|
|
Dec 01
2022
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
6,849
+2.24%
|
$13,698
$2.61 P/Share
|
|
Dec 01
2022
|
John Baldoni |
BUY
Grant, award, or other acquisition
|
Direct |
5,508
+25.05%
|
$11,016
$2.61 P/Share
|
|
Sep 15
2022
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
13,550
+50.0%
|
$27,100
$2.62 P/Share
|
|
Sep 15
2022
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
10,688
+50.0%
|
$21,376
$2.62 P/Share
|
|
Sep 15
2022
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
13,646
+50.0%
|
$27,292
$2.62 P/Share
|
|
Sep 15
2022
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
11,737
+50.0%
|
$23,474
$2.62 P/Share
|
|
Sep 15
2022
|
John Baldoni |
BUY
Grant, award, or other acquisition
|
Direct |
10,974
+50.0%
|
$21,948
$2.62 P/Share
|
|
Jul 19
2022
|
Ulf Wiinberg |
BUY
Open market or private purchase
|
Direct |
16,661
+5.29%
|
$16,661
$1.39 P/Share
|
|
Jul 18
2022
|
Ulf Wiinberg |
BUY
Open market or private purchase
|
Direct |
3,339
+1.17%
|
$3,339
$1.33 P/Share
|
|
Oct 19
2021
|
Agenus Inc |
SELL
Conversion of derivative security
|
Direct |
5,451,958
-17.15%
|
-
|
|
Oct 19
2021
|
Agenus Inc |
BUY
Open market or private purchase
|
Direct |
1,400,000
+6.28%
|
$16,800,000
$12.0 P/Share
|